JPMorgan raised the firm’s price target on Eli Lilly to $1,100 from $1,050 and keeps an Overweight rating on the shares. The firm increased the price target into the upcoming obesity catalysts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly resumed with a Buy at Citi
- Roche obesity pill tied to high rates of nausea in ST study, Bloomberg says
- Eli Lilly announces $1B expansion of Ireland manufacturing site
- Novo Nordisk rises as early weight-loss pill data impresses Street
- Eli Lilly says QWINT-2 trial met primary endpoint of non-inferior A1C reduction